Brief: HLS Therapeutics Files New Drug Submission For Perseris In Canada
23/01/2020 11:32
Jan 23 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS FILES NEW DRUG SUBMISSION FOR PERSERIS®
IN
CANADA
* HLS THERAPEUTICS INC - HLS IS SEEKING APPROVAL FOR
PERSERIS WITH
AN INDICATION FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS
* HLS THERAPEUTICS INC - NEW DRUG SUBMISSION FOR PERSERIS
WAS
ACCEPTED FOR REVIEW BY HEALTH CANADA ON JAN 23, 2020
Source text for Eikon: ID:nCNW1jcdja
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsBrief: Hls Therapeutics Increases Normal Course Issuer Bid
Brief: HLS Therapeutics Announces Q2 2026 Financial Results
Canada's HLS Therapeutics Q2 revenue rises on higher cardiovascular drugs demand
Brief: HLS Therapeutics - Secures Nilemdo Reimbursement With Private Payers Covering 80% Of Privately Insured Canadians
Canada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group